Výsledky vyhledávání - "Amer Methqal Zeidan"

Body mass index and venetoclax-hypomethylating agent induction therapy for acute myeloid leukemia

Autor: Julian J Weiss, Henry Le, Sonal Agarwal, Nikolai Alexandrovich Podoltsev, Amer Methqal Zeidan, Rory Shallis

Publikováno v: Journal of Clinical Oncology. 40:e19038-e19038

e19038 Background: Frontline Ven-HMA dosing is imperfectly estimated with HMA using body surface area (BSA) and Ven not BSA/weight-based. Not much is known if elevated body-mass-index (BMI) reduces drug exposure and impacts clinical outcomes with Ven

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e0cca2588394ec1b86987f7cf9c5b2a
https://doi.org/10.1200/jco.2022.40.16_suppl.e19038

Zobrazit plný text záznamu

Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial

Autor: Pierre Fenaux, Valeria Santini, Rami S. Komrokji, Amer Methqal Zeidan, Guillermo Garcia-Manero, Rena Buckstein, Dimana Miteva, Karen Keeperman, Natalia Holot, Jennie Zhang, Christina Hughes, Barbara Rosettani, Aylin Yucel, Uwe Platzbecker

Publikováno v: Journal of Clinical Oncology. 40:7056-7056

7056 Background: Luspatercept was previously shown to improve anemia in the phase 3 MEDALIST trial of pts with LR-MDS ineligible, intolerant, or refractory to erythropoiesis-stimulating agents (ESAs). Here, we report the long-term clinical value of l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8a5fe88b0a93e25e5658d1d14fcd48b9
https://doi.org/10.1200/jco.2022.40.16_suppl.7056

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání